ARCHIVES

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

This article is from The Cancer Letter archive.

Vol. 26 No. 11 | November 28, 2003

Download PDF Visit The Full Archive

Related Articles

John Niederhuber Named Acting NCI Director.

June 2, 2006

Group Chairmen Object To “Directive” Language In Proposed Intergroup Study Guidelines

January 13, 1984

Scientists Brief Writers On Progress In Cancer Research

April 18, 1975

Breast Removal Reduces Risk Of Cancer In BRCA Carriers

October 26, 2001

Clinical Research Program Announcement

February 13, 1981

In Brief: Bristol To Drop Angiostatin; Protein Fails To Meet Criteria For Development, Firm Says

February 12, 1999